7月21日，科伦博泰生物盘中上涨3.08%，报519.5港元，成交额6239.98万港元。
消息面上，近期多家国际投行密集上调公司目标价，摩根大通将目标价升至648港元，高盛上调至582.95港元并维持"买入"评级，瑞银看好公司全球扩张前景。核心产品sac-TMT联合帕博利珠单抗一线治疗PD-L1阴性非鳞状NSCLC的III期研究达主要终点，无进展生存期显著改善，总生存期亦呈积极趋势。此外，头部公募基金密集触及港股创新药标的举牌线，板块资金面持续向好，带动个股延续强势。
科伦博泰生物是一家主要从事肿瘤学、免疫学及其他治疗领域创新药物研发、制造及商业化的公司，核心产品包括TROP2 ADC等抗体药物偶联物。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.